Jean Murphy has already fought off breast cancer last year and she is now fighting kidney cancer and the government's denial of the therapy she needs to fight the disease.
Health bosses in Salford say they will not pay for Mrs Murphy from Salford, to have the drug which has doubled the life expectancy of other sufferers.
PRX321 has also been studied in a completed Phase 1 trial in which patients with recurrent, unresponsive metastatic renal cell and non-small cell lung carcinomas were treated.
A biomarker that may help doctors monitor the effectiveness of common treatments for kidney cancer and non-small cell lung cancer has been identified by researchers in the Netherlands.
Another successful clinical trial suggests that a bioartificial kidney to save the lives of people with acute renal failure will be available within a few years.
"It is a last hope. There's nowhere else she can go - this is it."
Five of the 11 patients are still alive.
Rh-Apo2L testing results have shown strong efficacy in treating kidney cancer and other malignancies.
This contributes to the relatively low five-year cancer survival rates for patients in Wales.
Dozens of donors have pledged $6.4 million to provide 40, four-year scholarships worth $160,000.
|NeonCRM by Neon One|